BBC, and a line of other media channels, has acknowledged Iconovo and its groundbreaking work with immunotherapy company ISR for the development of inhaled and nasal Covid-19 vaccines. Iconovo will develop the dry-powder formulation of the vaccine for ISR, which will be distributed with Iconovo’s single-use inhaler ICOone.
An inhaled Covid-19 vaccine will have several benefits, such as not requiring medical competence to administer, nor a cooling chain. Read more through the following links:
Swedish TV4 news feature